CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma
Authors:
- 15 August 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 122 (7) , 1233-1242
Abstract
Key Points: Brentuximab vedotin serves as an effective therapy for PEL. Brentuximab vedotin led to cytotoxic effects in PEL cell lines and extended survival of xenograft mice.Keywords
This publication has 34 references indexed in Scilit:
- Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphomaJournal of Clinical Investigation, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Kaposi's sarcoma and its associated herpesvirusNature Reviews Cancer, 2010
- Efficacy of bortezomib in a direct xenograft model of primary effusion lymphomaProceedings of the National Academy of Sciences, 2010
- Combination of the anti‐CD30‐auristatin‐E antibody‐drug conjugate (SGN‐35) with chemotherapy improves antitumour activity in Hodgkin lymphomaBritish Journal of Haematology, 2008
- CD30 in Normal and Neoplastic CellsClinical Immunology, 1999
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994
- Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's diseaseCell, 1992
- CD30 expression in non‐Hodgkin's lymphomaHistopathology, 1990